Differentiated thyroid cancer theranostics: radioiodine and beyond

Choudhury, Partha S; Gupta, Manoj

doi:10.1259/bjr.20180136

Cited by 73 publications

(49 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, patients with RAI-avid and 18 F-FDG negative lesions have a better prognosis. Patients with both 18 F-FDG and RAI uptake in the same lesion or in different lesions represent a very heterogeneous group, but their prognosis seems to be similar to the group with only 18 F-FDG uptake [63] Therefore, 18 F-FDG PET/CT could help to identify tumours or single lesions with an aggressive behavior that could benefit from other local or systemic therapies different from RAI (Fig. 4) [62].…”

Section: Radioiodine Therapymentioning

confidence: 99%

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

Nervo

Ragni

Retta

et al. 2020

J Endocrinol Invest

View full text Add to dashboard Cite

Bone represents the second most common site of distant metastases in differentiated thyroid cancer (DTC). The clinical course of DTC patients with bone metastases (BM) is quite heterogeneous, but generally associated with low survival rates. Skeletal-related events might be a serious complication of BM, resulting in high morbidity and impaired quality of life. To achieve disease control and symptoms relief, multimodal treatment is generally required: radioiodine therapy, local procedures-including surgery, radiotherapy and percutaneous techniques-and systemic therapies, such as kinase inhibitors and antiresorptive drugs. The management of DTC with BM is challenging: a careful evaluation and a personalized approach are essential to improve patients' outcomes. To date, prospective studies focusing on the main clinical aspects of DTC with BM are scarce; available analyses mainly include cohorts assembled over multiple decades, small samples sizes and data about BM not always separated from those regarding other distant metastases. The aim of this review is to summarize the most recent evidences and the unsolved questions regarding BM in DTC, analyzing several key issues: pathophysiology, prognostic factors, role of anatomic and functional imaging, and clinical management.

show abstract

Section: Radioiodine Therapymentioning

confidence: 99%

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

Nervo

Ragni

Retta

et al. 2020

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

“…In addition, SPECT/CT can clarify false positive uptake of I-131 due to sodium iodide symporter expression by tissues and consequent trapping to inflammation/infection, and to increased perfusion etc. (25,26). In cases with negative I-131 WBS and elevated serum thyroglobulin FDG-PET could detect all patients with metastatic cervical lymph nodes, while technetium-99m tetrofosmin SPECT as well as technetium -99m methoxyisobutylisonitrile SPECT could detect only a proportion of the affected patients (27,28).…”

Section: Discussionmentioning

confidence: 99%

I-131 Postablation SPECT/CT Predicts Relapse of Papillary Thyroid Carcinoma more Accurately than Whole Body Scan

Malamitsi

Koutsikos

Giourgouli

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: The aim of the study was to prospectively compare I-131 postablation Whole Body scan (WBS) and Single Photon Emission Computerized Tomography/Computerized Tomography (SPECT/CT) scan on thyroid cancer patients. Patients and Methods: Overall, 58 patients with papillary thyroid carcinoma were submitted to total thyroidectomy and I-131 remnant ablation. Postablation WBS and SPECT/CT scans performed on the same day were compared. Results of SPECT/CT were confirmed by neck and upper mediastinum ultrasound scan and on specific cases by a fully diagnostic CT scan, other tests and definitive histology acting as the gold standard. A total of 36/58 patients were followed-up for 5 years to detect relapse. Results: Mac Nemar Chi square and Fisher's exact tests disclosed statistically significant differences between WBS and SPECT/CT scan, concerning cervical lymphadenopathy detection (p=0.031) and relapse prediction by NM stage (p=0.033), respectively; SPECT/CT was more accurate in both comparisons. Conclusion: In papillary thyroid carcinoma I-131 post-ablation SPECT/CT scan detects cervical lymphadenopathy and predicts relapse by NM stage more accurately than WBS.

show abstract

“…While SPECT already has an important role in theranostics, there has been a recent surge of new theranostic applications using Lutetium-177 labelled peptides in neuroendocrine tumours, and PSMA in prostate cancer [85][86][87][88][89] with many other therapeutic areas in development by commercial partners [90]. Key to making the best use of this technology is the need to understand the radiation dose given to various tumour targets and organs at risk.…”

Section: Theranosticsmentioning

confidence: 99%

What scans we will read: imaging instrumentation trends in clinical oncology

et al. 2020

View full text Add to dashboard Cite

Oncological diseases account for a significant portion of the burden on public healthcare systems with associated costs driven primarily by complex and long-lasting therapies. Through the visualization of patient-specific morphology and functional-molecular pathways, cancerous tissue can be detected and characterized noninvasively, so as to provide referring oncologists with essential information to support therapy management decisions. Following the onset of stand-alone anatomical and functional imaging, we witness a push towards integrating molecular image information through various methods, including anato-metabolic imaging (e.g., PET/ CT), advanced MRI, optical or ultrasound imaging. This perspective paper highlights a number of key technological and methodological advances in imaging instrumentation related to anatomical, functional, molecular medicine and hybrid imaging, that is understood as the hardware-based combination of complementary anatomical and molecular imaging. These include novel detector technologies for ionizing radiation used in CT and nuclear medicine imaging, and novel system developments in MRI and optical as well as opto-acoustic imaging. We will also highlight new data processing methods for improved non-invasive tissue characterization. Following a general introduction to the role of imaging in oncology patient management we introduce imaging methods with well-defined clinical applications and potential for clinical translation. For each modality, we report first on the status quo and, then point to perceived technological and methodological advances in a subsequent status go section. Considering the breadth and dynamics of these developments, this perspective ends with a critical reflection on where the authors, with the majority of them being imaging experts with a background in physics and engineering, believe imaging methods will be in a few years from now. Overall, methodological and technological medical imaging advances are geared towards increased image contrast, the derivation of reproducible quantitative parameters, an increase in volume sensitivity and a reduction in overall examination time. To ensure full translation to the clinic, this progress in technologies and instrumentation is complemented by advances in relevant acquisition and image-processing protocols and improved data analysis. To this end, we should accept diagnostic images as "data", andthrough the wider adoption of advanced analysis, including machine learning approaches and a "big data" conceptmove to the next stage of non-invasive tumour phenotyping. The scans we will be reading in 10 years from now will likely be composed of highly diverse multidimensional data from multiple sources, which mandate the use of advanced and interactive visualization and

show abstract

Differentiated thyroid cancer theranostics: radioiodine and beyond

Cited by 73 publications

References 121 publications

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues

I-131 Postablation SPECT/CT Predicts Relapse of Papillary Thyroid Carcinoma more Accurately than Whole Body Scan

What scans we will read: imaging instrumentation trends in clinical oncology

Contact Info

Product

Resources

About